Antimitotic drugs cause increased tumorigenicity of multidrug resistant cells

International Journal of Oncology

Volumn 14, Issue 3, 1999, Pages 487-494

  Emanuel, Stuart L ^a,b   Chamberlin, Helena A ^a,b   Cohen, Dalia ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Alterations; Antimitotic drugs; Cell cycle; Kinase; Multidrug resistant

Indexed keywords

ANTINEOPLASTIC AGENT; CDK2 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLINE; ONCOPROTEIN; PACLITAXEL; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN SERINE THREONINE KINASE; VINBLASTINE;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVATION; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CDC2-CDC28 KINASES; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; NEOPLASMS; ONCOGENE PROTEINS V-RAF; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RETROVIRIDAE PROTEINS, ONCOGENIC; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0033093979     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.3.487     Document Type: Article

References (56)

1. Jordan MA and Wilson L: Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry 29: 2730-2739, 1990.
2. Wilson L, Anderson K, Grisham L and Chin D: Biochemical mechanisms of action of microtubule inhibitors. In: Microtubules and Microtubule Inhibitors, M. Borgers and M. de Brabander (eds.), North-Holland Publishing Co., Amsterdam, pp103-113, 1975.
3. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979.
4. Creasey WA: Modifications in biochemical pathways produced by the vinca alkaloids. Cancer Chemother Res 52: 501-507, 1968.
5. Crossin KL and Carney DH: Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 27: 341-350, 1981.
6. Jordan MA, Himes RH and Wilson L: Comparison of the effect of vincristine, vindesine and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res 45: 2741-2747, 1985.
7. Jordan MA, Thrower D and Wilson L: Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 51: 2212-2222, 1991.
8. Ding AH, Porteu F, Sanchez E and Nathan CF: Shared actions of endotoxin and taxol on TNF receptors and TNF-α release. Science 248: 370-372, 1990.
9. Manthey CL, Brandes ME, Perera PY and Vogel SN: Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein tyrosine phosphorylation in murine macrophages. J Immunol 149: 2459-2465, 1992.
10. Manthey CL, Perera P-Y, Salkowski CA and Vogel SN: Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 152: 825-831, 1994.
11. Ding AH, Sanchez E and Nathan CF: Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. J Immunol 151: 5596-5602, 1993.
12. Manthey CL, Qureshi N, Stütz PL and Vogel SN: Lipopolysaccharide antagonists block taxol-induced signalling in murine macrophages. J Exp Med 178: 695-702, 1993.
13. Sweet MJ and Hume DA: RAW264 macrophages stably transfected with an HIV-1 LTR reporter gene provide a sensitive bioassay for analysis of signalling pathways in macrophages stimulated with lipopolysaccharide, TNF-α or taxol. J Inflamm 45: 126-135, 1995.
14. Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW and Cohen D: Analysis of the interactions of SDZ PSC 833 ([3′-keto-BMT1]-Va12]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7: 603-610, 1995.
15. Mudryj M, Hiebert SW and Nevins JR: A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway. EMBO J 9: 2179-2184, 1990.
16. Hiebert SW, Blake M, Azizkhan J and Nevins JR: Role of E2F transcription factor in E1A-mediated trans activation of cellular genes. J Virol 65: 3547-3552, 1991.
17. DeCaprio JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Piwnica-Worms H, Huang C-H and Livingston DM: The product of the retinblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58: 1085-1095, 1989.
18. DeCaprio JA, Furukawa Y, Ajchenbaum F, Griffin JD and Livingston DM: The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci USA 89: 1795-1798, 1992.
19. Kaelin WG, Pallas DC, DeCaprio JA, Kaye FJ and Livingston DM: Identification of cellular proteins that can specifically interact with the T/E1a-binding region of the retinoblastoma gene product. Cell 64: 521-532, 1991.
20. Rustgi AK, Dyson N and Bernards R: Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product. Nature 358: 331-334, 1991.
21. Chittenden T, Livingston DM and Kaelin WG: The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence specific DNA-binding protein. Cell 65: 1073-1082, 1991.
22. Meyerson M and Harlow E: Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14: 2077-2086, 1994.
23. Kato J, Matsushime H, Hiebert SW, Ewen ME and Scherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Develop 7: 331-342, 1993.
24. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ and Kato J: D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14: 2066-2076, 1994.
25. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993.
26. Lew J, Beaudette K, Litvvin CME and Wang ME: Purification and characterization of a novel proline-directed protein kinase from bovine brain. J Biol Chem 267: 13383-13390, 1992.
27. Towbin H, Stadhelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4351, 1979.
28. cdc2 activation: identification of an activating kinase. Mol Biol Cell 3: 13-27, 1992.
29. Levedakou EN, He M, Baptist EW, Craven RJ, Cance WG, Welsch PL, Simmons A, Naylor SL, Leach RJ, Lewis TB, Bowcock A and Liu ET: Two novel human serine/threonine kinases with homologies to the cell cycle regulating Xenopus MO15, and NIMA kinases: cloning and characterization of their expression pattern. Oncogene 9: 1977-1988, 1994.
30. Blagosklonny MV, Schulte TW, Nguyen P, Trepel J and Neckers L: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851-1854, 1996.
31. Temin HM: Studies on carcinogenesis by avian sarcoma viruses. III. The differential effect of serum and polyanions on multiplication of uninfected and converted cells. J Natl Cancer Inst 37: 167-175, 1966.
32. Eagle H, Foley GE, Koprowski H, Lazarus H, Levine EM and Adams RA: Growth characteristics of virus-transformed cells. J Exp Med 131: 863-879, 1970.
33. Freedman VH and Shin S: Use of nude mice for studies on the tumorigenicity of animal cells. In: The Nude Mouse in Experimental and Clinical Research. J. Fogh and B.C. Giovanella (eds.) Academic Press, Inc., New York pp353-384, 1978.
34. Weinberg R: The retinoblastoma gene and cell growth control. Trends Biochem Sci 15: 199-202, 1990.
35. Weintraub SJ, Prater CA and Dean DC: Retinoblastoma protein switches the E2F site from a positive to negative element. Nature 358: 259-261, 1992.
36. Dalton S: Cell cycle regulation of the human cdc-2 gene. EMBO J 11: 1797-1804, 1992.
37. Zerfass K, Spitkovsky D, Schulze A, Joswig S, Henglein B and Jansen-Dürr P: Adenovirus E1A activates cyclin A gene transcription in the absence of growth factors through interaction with p107. J Virol 70: 2637-2642, 1996.
38. Lang JC, Wilkie NM, Clark AM, Chudleigh A, Talbot S, Whitelaw B and Frame MC: Regulatory domains within the PO promoter of human c-myc. Oncogene 6: 2067-2075, 1991.
39. Ku D-H, Wen S-C, Engelhard A, Nicolaides N, Lipson KE, Marino TA and Calabretta B: c-myb transactivates cdc2 expression via myb binding sites in the 5′-flanking region of the human cdc2 gene. J Biol Chem 268: 2255-2259, 1993.
40. 2-terminal domain of c-myc increases transactivation of gene expression. J Biol Chem 266: 23521-23524, 1991.
41. Seth A, Gonzalez FA, Gupta S, Raden DL and Davis R: Signal transduction within the nucleus by mitogen-activated protein kinase. J Biol Chem 267: 24796-24804, 1992.
42. Lee MG and Nurse P: Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 327: 31-35, 1987.
43. Kung AL, Sherwood SW and Schimke RT: Cell line specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci USA 87: 9553-9557, 1990.
44. Donaldson KL, Goolsby G, Kiener PA and Wahl AF: Activation of p34 cdc-2 coincident with taxol-induced apoptosis. Cell Growth Different 5: 1041-1050, 1994.
45. Westin EH, Wong-Staal F, Gelmann EP, Dalla Favera R, Papas TS, Lautenberger JA, Eva A, Reddy EP, Tronick SR, Aaronson SA and Gallo RC: Expression of cellular homologues of retroviral one genes in human hematopoietic cells. Proc Natl Acad Sci USA 79: 2490-2494, 1982.
46. Sozeri O, Vollmer K, Liyangae M, Frith D, Kour G, Mark III GE and Stabel S: Activation of the c-raf protein kinase by protein kinase C phosphorylation. Oncogene 7: 2259-2262, 1992.
47. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mishak H, Finkenzeller G, Marme D and Rapp UR: Protein kinase C alpha activates raf-1 by direct phosphorylation. Nature 364: 249-252, 1993.
48. Rapp UR: Role of raf-1 serine/threonine protein kinase in growth factor signal transduction. Oncogene 6: 495-500, 1991.
49. Heidecker G, Kölch W, Morrison D and Rapp UR: The role of raf-1 phosphorylation in signal transduction. Adv Cancer Res 58: 53-73, 1992.
50. Carboni JM, Singh C and Tepper MA: Taxol and lipopolysaccharide activation of a murine macrophage cell line and induction of similar tyrosine phosphoproteins. J Natl Cancer Inst Mono 15: 95-101, 1993.
51. WAF1 and p53 requires c-raf-1. Cancer Res 55: 4623-4626, 1995.
52. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J and Von Hoff D: A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9: 1261-1267, 1991.
53. Nakamura M, Kanda S, Kawamura M, Igawa T, Kanetake H and Saito Y: Effects of low concentration of vinblastine on the anchorage-independent growth and in vitro invasion of human renal carcinoma cell lines. Cancer Lett 69: 85-91, 1993.
54. Beketic-Oreskovic L, Durán GE, Chen G, Dumontet C and Sikic BI: Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87: 1593-1602, 1995.
55. Schneider J, Bak M, Efferth TH Kaufman M, Mattern J and VoIm M: P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60: 815-818, 1989.
56. Ro J, Sahin A, Ro JY, Fritsche J, Hortobagyi G and Blick M: Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21: 787-791, 1990.